Anlotinib hydrochloride, is a relatively widely used anti-tumor angiogenic drug. It was first used in the third-line treatment of advanced lung cancer for treatment after the progression of chemotherapy or targeted therapy. Currently, Anrotinib hydrochloride is increasingly used in lung cancer, ovarian cancer, cervical cancer and other tumors. The main effect is anti-tumor angiogenesis, which normalizes blood vessels and allows tumors to shrink significantly. However, its side effects are also mainly related to anti-tumor angiogenesis, which can lead to clinical manifestations such as hypertension and proteinuria. Severe hypertension can be grade 3 hypertension with systolic blood pressure above 180 mmHg and diastolic blood pressure above 110 mmHg, and proteinuria can also occur, even to the level of diagnosed nephrotic syndrome. Therefore, Anrotinib Hydrochloride has good anti-tumor angiogenic effect, but it can also lead to side effects such as high blood pressure and proteinuria.